InvestorsHub Logo
Followers 11
Posts 72
Boards Moderated 0
Alias Born 05/05/2018

Re: pgsd post# 485212

Friday, 06/10/2022 2:36:05 PM

Friday, June 10, 2022 2:36:05 PM

Post# of 710674
PGSD - thanks for posting. This piqued my interest so I've dug a little deeper. A friend has sent me the four page referenced article from a journal called Clinical Neuropharmacology (strikes me as an odd place for a piece about GBM). After reading it I would like to make several points:
1. The four authors of the paper, Drs. Long Tan, Jie Peng, Ping Liu and Qi Wu work at the The First Hospital of Changsha, Hunan Province China. None of them identify as neuro-oncologists (two identify as neurosurgeons, one as a respiratory doctor and one as an ER doctor).
2. The basis of the article is, and I quote, "We search PubMed, EMBASE, Web of science, EBSCO, and Cochrane library databases through December 2019 for randomized controlled trials assessing the efficacy and safety of dendritic cell vaccine for newly diagnosed glioblastoma."
3. Using this methodology they found three studies which matched this criteria - Buchroithner 2018, Cho 2012 and Wen 2019.
4. Two of the studies Cho and Buchroithner had very small enrollments (18 and 34 respectively) so the validity of these study results could be called into question.
5. However, and most importantly, NONE of these studies were conducted using DCVax.
6. Lastly, DCVax isn't even mentioned in the article.

In sum this journal article was done by doctors who are not neuro-oncolgists, conducted via web search, using studies with small sample sizes and most importantly NOT EVEN ABOUT DCVax. Furthermore neither DCVax nor NWBO are even mentioned in the journal article. Why on earth was this study was even referenced in the Cloughesy presentation is a mystery to me.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News